The Zantac Brand History — Multiple Owners, One Molecule
Branded Zantac has had multiple corporate owners since ranitidine was first developed. The drug was originally discovered and developed by Glaxo (later GlaxoSmithKline / GSK), which introduced Zantac to the U.S. market in 1983 and held the brand through its patent protection period. After patent expiration, Pfizer acquired the Zantac brand and related OTC consumer healthcare assets from GSK's consumer division. Sanofi S.A. subsequently acquired Pfizer's consumer healthcare unit, including Zantac, making Sanofi the most recent owner of the Zantac brand at the time of the FDA market withdrawal in April 2020. All three companies — GSK, Pfizer, and Sanofi — are named defendants in Zantac litigation, and claimants' exposure periods may cover one or more of their respective tenure periods as Zantac brand holders.
Generic Ranitidine Manufacturers — The Same Liability
Boehringer Ingelheim is the most significant generic ranitidine manufacturer in Zantac litigation. Boehringer Ingelheim manufactured and distributed generic ranitidine products under private label and retailer-brand agreements, making its products widely available across major retail chains as store-brand antacids. Other generic manufacturers also produced and distributed ranitidine, and their products are equally implicated because the NDMA issue arises from the ranitidine API (active pharmaceutical ingredient) itself, not from any specific excipient or manufacturing process used by a particular company. Store-brand ranitidine sold by CVS Health, Walgreens Boots Alliance, Walmart, Target, Rite Aid, Costco, and other retailers is also covered by litigation — the store brand designations merely identify the retailer; the underlying API came from generic manufacturers who are named defendants.
Why Multiple Defendants Benefit Claimants
The availability of multiple defendant companies with substantial financial resources and insurance coverage is a significant practical advantage for Zantac claimants. Unlike litigation against a single small manufacturer that might declare bankruptcy and limit recoveries, the Zantac defendants — Sanofi (a major global pharmaceutical company), GSK (one of the world's largest pharmaceutical companies), Pfizer (the world's largest pharmaceutical company by certain metrics), and Boehringer Ingelheim (a privately held multinational) — collectively represent some of the most financially solvent companies in the world. Even if one defendant prevails at trial or reaches an early global settlement, other defendants remain in the litigation. Claimants who used both branded Zantac and generic ranitidine over their use history may have claims against multiple defendants.
How to Identify Which Manufacturer Made Your Ranitidine
Many consumers who took ranitidine over years purchased both branded Zantac and generic or store-brand versions interchangeably — whichever was on sale or available at the time. Pharmacy records typically identify the manufacturer or distributor for prescription fills. For OTC purchases, store loyalty card data, credit card statements, and receipts may identify the retailer, from which the generic manufacturer can often be identified through the store's private-label supplier relationships. In practice, plaintiff's attorneys often name multiple defendants and establish that the claimant used ranitidine products from multiple manufacturers over their exposure period, supporting claims against the entire pool of defendants.
Frequently Asked Questions
Related Pages
Zantac NDMA Contamination Explained
NDMA contamination in Zantac is not an external manufacturing defect — it is an inherent property of the ranitidine molecule itself. Ranitidine is chemically unstable and generates NDMA as a degradation product, and additional NDMA is produced inside the human body during ranitidine metabolism. This made Zantac fundamentally dangerous regardless of which manufacturer produced it.
The Valisure Study — How the NDMA Problem Was Discovered
Valisure LLC, an independent pharmaceutical testing laboratory in New Haven, Connecticut, discovered the NDMA problem in ranitidine in 2019 and filed a Citizen Petition with the FDA that triggered the events leading to the April 2020 market withdrawal. Valisure's methodology was initially contested but has been substantially vindicated by subsequent independent research.
Zantac Settlement Expectations — State Court Litigation 2026
Zantac state court litigation in 2026 is in an active but early phase compared to fully mature mass torts. Bellwether trials in Delaware will begin to establish settlement values for the broader case pool. Settlement ranges of $200,000 to $3,000,000 are estimated for qualifying claims, with strong Stage IV/wrongful death cases commanding the highest values. Do not expect quick settlements — state court mass torts typically take years.
Zantac Statute of Limitations — State-by-State 2026 Analysis
The statute of limitations for Zantac cancer claims varies by state, typically 2 to 3 years from the date of cancer diagnosis or from when the claimant knew or should have known of the Zantac-cancer connection (the discovery rule). The April 2020 FDA withdrawal is often cited as the constructive notice date. Claimants with diagnoses from 2022 onward and those who can show delayed discovery may still have timely claims in 2026.
Cancers Covered by Zantac Litigation
Six cancer types are the primary qualifying diagnoses in active Zantac state court litigation in 2026: bladder, stomach, colorectal, esophageal, breast, and prostate cancers. Bladder and gastrointestinal cancers have the most robust scientific and epidemiological support. Strength of causation evidence and state court acceptance varies by cancer type, and an attorney can evaluate your specific diagnosis.
Zantac and Bladder Cancer
Bladder cancer is the cancer most strongly and consistently linked to NDMA exposure from ranitidine. NDMA is excreted in urine, directly bathing the bladder epithelium in the carcinogen. Bladder cancer carries a high recurrence rate even after successful treatment, meaning lifetime surveillance and repeat procedures create substantial ongoing medical costs that factor significantly into claim values.
Zantac Federal MDL Dismissal — What Happened
The federal MDL in the Southern District of Florida was dismissed in November 2022 after Judge Robin Rosenberg excluded all of the plaintiffs' general causation experts under the Daubert standard. This ruling applies only to federal court. It does not bind state courts. Active Zantac litigation continues in Delaware and California state courts in 2026 under different evidentiary standards.
Zantac State Court Litigation — Delaware and California 2026
Following the closure of the federal MDL in November 2022, Zantac litigation has continued and grown in state courts. Delaware Superior Court is the most active venue, with thousands of consolidated cases proceeding under coordinated case management orders. California state courts have also produced favorable rulings for plaintiffs. State court proceedings are independent of the federal MDL and proceed on their own timelines in 2026.
Zantac Eligibility Requirements
To qualify for a Zantac cancer claim in 2026, you generally need: (1) at least 1 year of regular Zantac or ranitidine use; (2) a diagnosis of a qualifying cancer type; (3) a medically plausible timeline between use and diagnosis; and (4) a claim that falls within your state's statute of limitations. State court filings are active in Delaware and California.
FDA Zantac Market Withdrawal — April 2020
On April 1, 2020, the FDA formally requested that all ranitidine manufacturers withdraw their products from the U.S. market. This unprecedented action — covering both prescription and OTC products from all manufacturers — marked the FDA's conclusion that the NDMA problem in ranitidine was unfixable and that ranitidine products posed an unacceptable cancer risk for consumers.
Proving Zantac Use — How to Obtain Pharmacy Records
Pharmacy records are the single strongest form of evidence of long-term Zantac use for litigation purposes. Major pharmacy chains maintain prescription records and often OTC purchase histories for many years. Your attorney can assist in obtaining these records through HIPAA authorizations and subpoenas.
Zantac / Ranitidine (NDMA Cancer) Lawsuit
Ranitidine, sold under the brand name Zantac by Sanofi and previously by GSK, Pfizer, and Boehringer Ingelheim, was one of the most prescribed heartburn and acid reflux medications in history. In 2019, the independent pharmaceutical testing laboratory Valisure discovered that ranitidine is inherently unstable and produces NDMA — N-nitrosodimethylamine, a probable human carcinogen — at levels up to 304,500 nanograms per tablet. The FDA acceptable daily intake limit for NDMA is 96 nanograms. In April 2020, the FDA requested that all manufacturers withdraw ranitidine products from the U.S. market. Consumers who took Zantac regularly for a year or more and subsequently developed bladder, stomach, colorectal, breast, prostate, or esophageal cancer may have viable legal claims. A federal MDL in the Southern District of Florida was dismissed in November 2022 when Judge Robin Rosenberg excluded plaintiffs' general causation experts under Daubert, finding their methodologies unreliable. However, that ruling applies only to federal court and does not bind state courts. Litigation continues in Delaware Superior Court and California state courts in 2026, where different expert standards and case-specific evidence can support claims.
View full case overview